ライフサイエンスコーパス: immunodeficiency syndrome

1 s against HIV, the culprit of AIDS (acquired immunodeficiency syndrome).

2 patients died (unrelated to HIV or acquired immunodeficiency syndrome).

3 I treatment adjunctively in HIV and acquired immunodeficiency syndrome.

4 nts <350 cells/mm(3) and 2 (7%) had acquired immunodeficiency syndrome.

5 rus (SIV)-infected macaque model of acquired immunodeficiency syndrome.

6 , tyrosine kinase 2, underlies another human immunodeficiency syndrome.

7 m cell genesis in mice is mutated in a human immunodeficiency syndrome.

8 ed patients with cancer or advanced acquired immunodeficiency syndrome.

9 een found to cause the human severe combined immunodeficiency syndrome.

10 sease, and wasting associated with the human immunodeficiency syndrome.

11 ptoms), and deaths were ascribed to acquired immunodeficiency syndrome.

12 tion, muscle weakness, and a severe combined immunodeficiency syndrome.

13 e, and human immunodeficiency virus/acquired immunodeficiency syndrome.

14 viral persistence in patients with acquired immunodeficiency syndrome.

15 DHPS mutations in 107 patients with acquired immunodeficiency syndrome.

16 pproved by the FDA for treatment of acquired immunodeficiency syndrome.

17 the context of immunodeficiency and acquired immunodeficiency syndrome.

18 eficiency virus (HIV) infection and acquired immunodeficiency syndrome.

19 irus infection and delayed onset of acquired immunodeficiency syndrome.

20 tive states, immune cytopenias, and acquired immunodeficiency syndrome.

21 een described only in patients with acquired immunodeficiency syndrome.

22 llite regions are characteristic for the ICF immunodeficiency syndrome.

23 ho family of GTPases associated with a human immunodeficiency syndrome.

24 unistic infections in patients with acquired immunodeficiency syndrome.

25 e vascular injury syndromes seen in acquired immunodeficiency syndrome.

26 tion, particularly in patients with acquired immunodeficiency syndrome.

27 thway as a genetic etiology for this primary immunodeficiency syndrome.

28 Irgm1 deficiency is associated with a severe immunodeficiency syndrome.

29 STK4 deficiency is a novel human primary immunodeficiency syndrome.

30 been identified in a patient with hyper-IgM immunodeficiency syndrome.

31 ition of H3K4me3 is mutated in patients with immunodeficiency syndromes.

32 mutants are also mutated in human inherited immunodeficiency syndromes.

33 cumented in the treatment of severe combined immunodeficiency syndromes.

34 ndrome, distinct from other types of HED and immunodeficiency syndromes.

35 lvin D1 in the treatment of XLP-2 and innate immunodeficiency syndromes.

36 lative risk of death related to the acquired immunodeficiency syndrome (0.73; 95 percent confidence i

37 rson-years, 268 of 614 men incurred acquired immunodeficiency syndrome, 49 died, and 90 were lost to

38 nodeficiency virus infection or the acquired immunodeficiency syndrome (7 percent each).

39 r infection and 5-year incidence of acquired immunodeficiency syndrome, adjusting for (continuous) ag

40 seline plasma from 619 persons with acquired immunodeficiency syndrome (AIDS) (median CD4+ lymphocyte

41 njection drug use on 6-year risk of acquired immunodeficiency syndrome (AIDS) after initiation of com

42 igate the validity of self-reported acquired immunodeficiency syndrome (AIDS) among women enrolled in

43 associations with incident clinical acquired immunodeficiency syndrome (AIDS) and CD4+ T cell count d

44 irus (HIV)-infected men at risk for acquired immunodeficiency syndrome (AIDS) and followed between Ja

45 amatically reduced the incidence of acquired immunodeficiency syndrome (AIDS) and increased AIDS surv

46 myelinolysis), infections [malaria, acquired immunodeficiency syndrome (AIDS) and infection with huma

47 t a correlation between severity of acquired immunodeficiency syndrome (AIDS) and selenium deficiency

48 In 1981, the acquired immunodeficiency syndrome (AIDS) appeared insidiously an

49 alitis and dementia associated with acquired immunodeficiency syndrome (AIDS) are characterized by le

50 sit to the clinic and being free of acquired immunodeficiency syndrome (AIDS) at enrollment.

51 rs or older who were diagnosed with acquired immunodeficiency syndrome (AIDS) between January 1, 1985

52 A total of 1600 participants with acquired immunodeficiency syndrome (AIDS) but without CMV retinit

53 linical trial to assess the risk of acquired immunodeficiency syndrome (AIDS) by timing of therapy.

54 the cumulative survival benefits of acquired immunodeficiency syndrome (AIDS) care in the United Stat

55 stimating the prevented fraction of acquired immunodeficiency syndrome (AIDS) cases attributable to s

56 sent an increasing proportion of US acquired immunodeficiency syndrome (AIDS) cases, few research stu

57 for certain biliary diseases, e.g., acquired immunodeficiency syndrome (AIDS) cholangiopathy and graf

58 ryptosporidiosis is associated with acquired immunodeficiency syndrome (AIDS) cholangiopathy and occu

59 virus (HIV) infections and averting acquired immunodeficiency syndrome (AIDS) deaths in the San Franc

60 Declines in the number of acquired immunodeficiency syndrome (AIDS) deaths were first obser

61 urred in one patient (25%), all non-acquired immunodeficiency syndrome (AIDs) defining.

62 fected brain in relationship to the acquired immunodeficiency syndrome (AIDS) dementia complex (ADC)

63 gressive immune dysfunction and the acquired immunodeficiency syndrome (AIDS) develop in most persons

64 unodeficiency virus (HIV) infection/acquired immunodeficiency syndrome (AIDS) epidemic has grown from

65 human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) epidemic is the difficu

66 ccine is critical to end the global acquired immunodeficiency syndrome (AIDS) epidemic, but many ques

67 Early in the acquired immunodeficiency syndrome (AIDS) epidemic, epidemiologic

68 enes for stem cell gene therapy for acquired immunodeficiency syndrome (AIDS) has been limited by the

69 Persons with acquired immunodeficiency syndrome (AIDS) have a higher incidence

70 cytomegalovirus (CMV) retinitis and acquired immunodeficiency syndrome (AIDS) have required lifelong

71 mainly due to the emergence of the acquired immunodeficiency syndrome (AIDS) in 25- to 64-year-olds

72 virus type 1 (HIV-1), the cause of acquired immunodeficiency syndrome (AIDS) in humans, efficiently

73 m sooty mangabeys, are the cause of acquired immunodeficiency syndrome (AIDS) in humans.

74 e 1 (HIV-1), the etiologic agent of acquired immunodeficiency syndrome (AIDS) in humans.

75 e focused on access to treatment of acquired immunodeficiency syndrome (AIDS) in poor, severely affec

76 ciency virus (HIV) infection or the acquired immunodeficiency syndrome (AIDS) in sub-Saharan Africa.

77 owever, SIVs do not generally cause acquired immunodeficiency syndrome (AIDS) in their natural hosts.

78 n is a key factor in progression to acquired immunodeficiency syndrome (AIDS) in untreated HIV-infect

79 Acquired immunodeficiency syndrome (AIDS) is principally a diseas

80 As people with acquired immunodeficiency syndrome (AIDS) live longer, the preval

81 a high viral set point progress to acquired immunodeficiency syndrome (AIDS) more rapidly than those

82 nderstand recent temporal trends in acquired immunodeficiency syndrome (AIDS) mortality in the era of

83 sk (RR) for clinical progression to acquired immunodeficiency syndrome (AIDS) of 1.66 (95% confidence

84 human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) on demand for health ca

85 class I loci (A, B, and C) delayed acquired immunodeficiency syndrome (AIDS) onset among patients in

86 ter or until the development of the acquired immunodeficiency syndrome (AIDS) or another condition th

87 e antiretroviral therapy on time to acquired immunodeficiency syndrome (AIDS) or death in 1,498 US me

88 al therapy initiation with incident acquired immunodeficiency syndrome (AIDS) or death while accounti

89 troviral therapy (HAART) on time to acquired immunodeficiency syndrome (AIDS) or death, the authors u

90 ly needed to curb the growth of the acquired immunodeficiency syndrome (AIDS) pandemic and ultimately

91 strategies that aim to contain the acquired immunodeficiency syndrome (AIDS) pandemic.

92 The hallmark of acquired immunodeficiency syndrome (AIDS) pathogenesis is a progr

93 d populations compared with similar acquired immunodeficiency syndrome (AIDS) patients in the United

94 CSF samples from 15 acquired immunodeficiency syndrome (AIDS) patients with biopsy-pr

95 dy reports the surgical outcomes of acquired immunodeficiency syndrome (AIDS) patients with Cytomegal

96 ncers that occur at higher rates in acquired immunodeficiency syndrome (AIDS) patients, the cancer ex

97 and drives systemic inflammation in acquired immunodeficiency syndrome (AIDS) patients.

98 n a new host is a critical goal for acquired immunodeficiency syndrome (AIDS) research.

99 Most acquired immunodeficiency syndrome (AIDS) service providers are i

100 isease incidence among persons with acquired immunodeficiency syndrome (AIDS) since the introduction

101 n alveolar macrophages and PMN from acquired immunodeficiency syndrome (AIDS) subjects, we investigat

102 authors assessed temporal trends in acquired immunodeficiency syndrome (AIDS) survival for 15,271 per

103 sociated with markedly enhanced HIV/acquired immunodeficiency syndrome (AIDS) susceptibility.

104 irus (HIV) among cases who obtained acquired immunodeficiency syndrome (AIDS) through heterosexual co

105 associated with communication about acquired immunodeficiency syndrome (AIDS) through social networks

106 e authors compared 1,642 women with acquired immunodeficiency syndrome (AIDS) to 8,443 uninfected wom

107 monkeys with acute SIV infection or acquired immunodeficiency syndrome (AIDS) underwent normal matura

108 -based natural-history cohorts with acquired immunodeficiency syndrome (AIDS) were genotyped for 21 s

109 us (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) who are receiving highl

110 ptosporidiosis in patients with the acquired immunodeficiency syndrome (AIDS), and went on to study i

111 irus retinitis in patients with the acquired immunodeficiency syndrome (AIDS), but it does not treat

112 he likelihood of progression to the acquired immunodeficiency syndrome (AIDS), but the relation betwe

113 wed from seroconversion to incident acquired immunodeficiency syndrome (AIDS), death, or the beginnin

114 type 1 (HIV-1), the cause of human acquired immunodeficiency syndrome (AIDS), is a zoonotic infectio

115 rus type 1 (HIV-1) infection to the acquired immunodeficiency syndrome (AIDS), it appears that the st

116 o measure, as a model of wasting in acquired immunodeficiency syndrome (AIDS), longitudinal body-comp

117 luded in the case definition of the acquired immunodeficiency syndrome (AIDS), non-AIDS-defining canc

118 prevalence and mortality induced by acquired immunodeficiency syndrome (AIDS), provided the case repr

119 deaths among people diagnosed with acquired immunodeficiency syndrome (AIDS), the authors determined

120 human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), tuberculosis (TB), and

121 e activation predict progression to acquired immunodeficiency syndrome (AIDS), we evaluated the assoc

122 troviral therapy, which can prevent acquired immunodeficiency syndrome (AIDS)-associated events, rest

123 Patients with acquired immunodeficiency syndrome (AIDS)-associated non-Hodgkin

124 IV)-infected macaques as a model of acquired immunodeficiency syndrome (AIDS)-associated P. carinii p

125 The acquired immunodeficiency syndrome (AIDS)-causing lentiviruses hu

126 d by disease severity defined as an acquired immunodeficiency syndrome (AIDS)-defining event or low C

127 n of LTF on estimated rates of LTF, acquired immunodeficiency syndrome (AIDS)-defining events, and de

128 Ten individuals developed acquired immunodeficiency syndrome (AIDS)-defining events.

129 have a new (previously undiagnosed) acquired immunodeficiency syndrome (AIDS)-defining illness at 48

130 roviral therapy (HAART) on multiple acquired immunodeficiency syndrome (AIDS)-defining illnesses rema

131 y CD4(+) levels associated with the acquired immunodeficiency syndrome (AIDS)-free time equivalent to

132 The acquired immunodeficiency syndrome (AIDS)-protective chemokine re

133 We assessed non-liver-related non-acquired immunodeficiency syndrome (AIDS)-related (NLR-NAR) event

134 r investigating the pathogenesis of acquired immunodeficiency syndrome (AIDS)-related cytopenias.

135 rmine whether microbiologic cure of acquired immunodeficiency syndrome (AIDS)-related disseminated cr

136 etermine the role that a hospital's acquired immunodeficiency syndrome (AIDS)-related experience may

137 iency virus (HIV) have shifted from acquired immunodeficiency syndrome (AIDS)-related illnesses to ch

138 study of IL-12 in 32 patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma

139 nt in the early pathogenesis of the acquired immunodeficiency syndrome (AIDS)-related lymphoma (ARL).

140 ARL (acquired immunodeficiency syndrome (AIDS)-related lymphoma) and n

141 time-varying incident TB on time to acquired immunodeficiency syndrome (AIDS)-related mortality using

142 ed that prior to the development of acquired immunodeficiency syndrome (AIDS)-related pulmonary compl

143 atric Burkitt's lymphomas (BL), two acquired immunodeficiency syndrome (AIDS)-related type I latency

144 lopment of a preventive vaccine for acquired immunodeficiency syndrome (AIDS).

145 virus (SIV) very rarely progress to acquired immunodeficiency syndrome (AIDS).

146 nal increases in incidence rates of acquired immunodeficiency syndrome (AIDS).

147 tunistic infection of patients with acquired immunodeficiency syndrome (AIDS).

148 nfection in untreated patients with acquired immunodeficiency syndrome (AIDS).

149 and its predictors in children with acquired immunodeficiency syndrome (AIDS).

150 e chronic diarrhea in patients with acquired immunodeficiency syndrome (AIDS).

151 ne as a cofactor for development of acquired immunodeficiency syndrome (AIDS).

152 inal disease are common features of acquired immunodeficiency syndrome (AIDS).

153 degeneration (AMD) in patients with acquired immunodeficiency syndrome (AIDS).

154 retinitis in 160 patients with the acquired immunodeficiency syndrome (AIDS).

155 nes in morbidity and mortality from acquired immunodeficiency syndrome (AIDS).

156 Pneumocystis carinii pneumonia and acquired immunodeficiency syndrome (AIDS).

157 factor in the immunopathogenesis of acquired immunodeficiency syndrome (AIDS).

158 infectivity and the progression to acquired immunodeficiency syndrome (AIDS).

159 human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS).

160 ation of pneumonia in patients with acquired immunodeficiency syndrome (AIDS).

161 adoptive transfer to a patient with acquired immunodeficiency syndrome (AIDS).

162 transmitted diseases, including the acquired immunodeficiency syndrome (AIDS).

163 ction, is a principal driver of the acquired immunodeficiency syndrome (AIDS).

164 loads and more rapid progression to acquired immunodeficiency syndrome (AIDS).

165 dity and mortality in patients with acquired immunodeficiency syndrome (AIDS).

166 orce of CD4(+) T-cell depletion and acquired immunodeficiency syndrome (AIDS).

167 HIV-1 infection and progression to acquired immunodeficiency syndrome (AIDS).

168 tomach and esophagus in people with acquired immunodeficiency syndrome (AIDS).

169 target for design of drugs against acquired immunodeficiency syndrome (AIDS).

170 s-specific SIVs, but do not develop acquired immunodeficiency syndrome (AIDS).

171 n since the earliest recognition of acquired immunodeficiency syndrome (AIDS).

172 Five patients had acquired immunodeficiency syndrome (AIDS); one had common variabl

173 n (rIFN)- gamma 1b in patients with acquired immunodeficiency syndrome and acute cryptococcal meningi

174 ture isolates from 87 patients with acquired immunodeficiency syndrome and CMV retinitis who received

175 stance was studied in patients with acquired immunodeficiency syndrome and CMV retinitis.

176 an increased risk of progression to acquired immunodeficiency syndrome and death, a relationship that

177 assically reported in patients with acquired immunodeficiency syndrome and emerged as a cause of pers

178 lcohol consumption (one of whom had acquired immunodeficiency syndrome and hepatitis B), one was posi

179 ical parameters among patients with acquired immunodeficiency syndrome and histoplasmosis in Brazil a

180 ted by human immunodeficiency virus/acquired immunodeficiency syndrome and other infectious diseases,

181 uman immunodeficiency virus-related acquired immunodeficiency syndrome and other infectious diseases.

182 incarceration and reported cases of acquired immunodeficiency syndrome and syphilis were weak (r=0.20

183 PIDs increases as researchers discover novel immunodeficiency syndromes and as clinicians increasingl

184 egulated expression is associated with human immunodeficiency syndromes and vascular integrity, it is

185 diosensitivity, predisposition to cancer and immunodeficiency syndromes, and the analysis of the unde

186 Emerging evidence indicates that innate immunodeficiency syndromes are linked to mutations in in

187 accumulation relevant to a broad variety of immunodeficiency syndromes as well as to diseases and di

188 tivate Artemis cause a human severe combined immunodeficiency syndrome associated with cellular radio

189 sregulation (PLAID) is a newly characterized immunodeficiency syndrome associated with distinct cutan

190 are responsible for a rare primary combined immunodeficiency syndrome associated with severe cutaneo

191 Novel immunodeficiency syndromes associated with mutations in

192 tal infection, transplantation, and acquired immunodeficiency syndrome-associated CMV diseases.

193 the disease burden in patients with acquired immunodeficiency syndrome-associated tuberculosis.

194 n syndrome has been proposed to be a primary immunodeficiency syndrome because of the high frequency

195 Records of people diagnosed with acquired immunodeficiency syndrome between 1993 and 2007 in Flori

196 alignancy, storage diseases, BM failure, and immunodeficiency syndromes between 1991 and 1999.

197 's first case involving HIV and the acquired immunodeficiency syndrome, Bragdon v Abbott, addressed t

198 However, the acquired immunodeficiency syndrome, breast cancer, diabetes melli

199 TB accelerates acquired immunodeficiency syndrome by increasing human immunodefi

200 ion and is defective in the human hereditary immunodeficiency syndrome called bare lymphocyte syndrom

201 troviral inoculum, LP-BM5, which produces an immunodeficiency syndrome called murine AIDS (MAIDS).

202 etiologic defective virus (BM5def) causes an immunodeficiency syndrome called murine AIDS (MAIDS).

203 package of services provided by HIV/acquired immunodeficiency syndrome care and treatment programs in

204 allelic IRF8 deficiency, revealing a complex immunodeficiency syndrome caused by DC and monocyte defi

205 in 6 patients with a newly described genetic immunodeficiency syndrome caused by mutations in GATA2-a

206 na) with one isolate of SIVagm results in an immunodeficiency syndrome characterized by progressive C

207 Haploinsufficiency for GATA2 causes human immunodeficiency syndromes characterized by mycobacteria

208 tates effective newborn screening for severe immunodeficiency syndromes characterized by the absence

209 rolled at 28 sites of the Pediatric Acquired Immunodeficiency Syndrome Clinical Trials Group.

210 ere participants in the Multicenter Acquired Immunodeficiency Syndrome Cohort Study for GBV-C viremia

211 differences in the incidence of the acquired immunodeficiency syndrome, death, or serious adverse eve

212 )/L and 549 x 10(6)/L without prior acquired immunodeficiency syndrome-defining conditions receiving

213 reas patients who developed another acquired immunodeficiency syndrome-defining illness did not.

214 ed to determine predictors of a new acquired immunodeficiency syndrome-defining illness or death.

215 focal leukoencephalopathy (PML), an acquired immunodeficiency syndrome-defining illness.

216 and CIN, and cervical cancer is an acquired immunodeficiency syndrome-defining illness.

217 percent of the patients had had an acquired immunodeficiency syndrome-defining illness.

218 function and presents clinically as acquired immunodeficiency syndrome dementia complex (ADC).

219 munodeficiency, all 4 subjects with acquired immunodeficiency syndrome dementia complex had R5 tropis

220 NTS, including autoimmune diseases, acquired immunodeficiency syndrome, diabetes, cirrhosis, transpla

221 The proportion of acquired immunodeficiency syndrome diagnoses in which wasting was

222 Having an acquired immunodeficiency syndrome diagnosis or multiple Salmonel

223 netic association with HIV-1 and/or acquired immunodeficiency syndrome disease progression in an Afri

224 The findings define a new X-linked recessive immunodeficiency syndrome, distinct from other types of

225 nal caspase-8 in T cells manifest a profound immunodeficiency syndrome due to defective T cell antige

226 ical presentation in the era of the acquired immunodeficiency syndrome epidemic.

227 1 (HIV-1) and those affected by the acquired immunodeficiency syndrome epidemic.

228 2 ALIVE scientists and an expert in acquired immunodeficiency syndrome epidemiology about the relatio

229 s attending a county outpatient HIV/acquired immunodeficiency syndrome facility were referred for the

230 , regarding estimation of long-term acquired immunodeficiency syndrome-free survival to demonstrate t

231 Genetic identification of immunodeficiency syndromes has become more efficient wit

232 link between autoimmune diseases and primary immunodeficiency syndromes has been increasingly appreci

233 the incidence of and mortality from acquired immunodeficiency syndrome have declined recently in the

234 als both positive and negative for the human immunodeficiency syndrome (HIV) in the Multicenter AIDS

235 an immunodeficiency virus infection/acquired immunodeficiency syndrome (HIV/AIDS) (OR = 4.27; CI, 1.5

236 led-up human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) care and treatment

237 Human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) is one of the leadi

238 betes, human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), arthritis, inflamm

239 or if an illness indicative of the acquired immunodeficiency syndrome (i.e., an AIDS-defining illnes

240 BM5 murine leukemia virus causes an acquired immunodeficiency syndrome in C57BL/6 mice (MAIDS) and im

241 is often the first manifestation of acquired immunodeficiency syndrome in patients infected with huma

242 auses an AIDS-like syndrome--murine acquired immunodeficiency syndrome--in C57B1/6 mice and impairs s

243 Human immunodeficiency syndrome infection was more common in O

244 biallelic mutations in VPS45 underlies a new immunodeficiency syndrome involving impaired neutrophil

245 dominant forms of the hyper-IgE syndrome, an immunodeficiency syndrome involving increased innate imm

246 hown that DOCK8, a gene mutated in a primary immunodeficiency syndrome, is involved in NK cell killin

247 duces the mortality of persons with acquired immunodeficiency syndrome, it does not eliminate HIV res

248 ction drug users recruited into the Acquired Immunodeficiency Syndrome Link to Intravenous Experience

249 In nonhuman primate models of acquired immunodeficiency syndrome, live attenuated lentiviruses

250 Since mice with retrovirus-induced immunodeficiency syndrome (MAIDS) exhibited a frequency

251 odeficiency virus infection and the acquired immunodeficiency syndrome, medical malpractice, and the

252 The immunodeficiency syndrome murine AIDS (MAIDS), caused by

253 Deaths from acquired immunodeficiency syndrome occurred exclusively among pro

254 morphic Artemis mutations result in combined immunodeficiency syndromes of varying severity, but, in

255 ate therapy prior to progression to acquired immunodeficiency syndrome or death by both measures of a

256 pout, the weighted hazard ratio for acquired immunodeficiency syndrome or death comparing use of high

257 antiretroviral therapy on incident acquired immunodeficiency syndrome or death, the authors combined

258 tiretroviral therapy, 211 developed acquired immunodeficiency syndrome or died, and 173 dropped out.

259 s with human immunodeficiency virus/acquired immunodeficiency syndrome or substance abuse (family pra

260 8-0.57) and increased with comorbid acquired immunodeficiency syndrome (OR 4.52, CI 3.01-6.79).

261 begun to mitigate the impact of the acquired immunodeficiency syndrome pandemic.

262 r has become increasingly common in acquired immunodeficiency syndrome patients but has only rarely b

263 l cord dorsal horn (SDH) from HIV-1/acquired immunodeficiency syndrome patients who developed chronic

264 s with human immunodeficiency virus/acquired immunodeficiency syndrome, patients receiving therapeuti

265 erologic diagnosis of HIV, from the acquired immunodeficiency syndrome program of the Health Center o

266 eningitis accounts for 20 to 25% of acquired immunodeficiency syndrome-related deaths in Africa.

267 5% of patients with newly diagnosed acquired immunodeficiency syndrome-related lymphoma (ARL).

268 terologous stem cell transplant for acquired immunodeficiency syndrome-related lymphoma from a CCR5(-

269 The outcome of acquired immunodeficiency syndrome-related lymphomas (ARLs) has i

270 Recent dramatic decreases in acquired immunodeficiency syndrome-related mortality are largely

271 to evaluate the effect of HAART on acquired immunodeficiency syndrome-related mortality, adjusting f

272 ecause the incidence of traditional acquired immunodeficiency syndrome-related opportunistic infectio

273 mmunodeficiency virus infection and acquired immunodeficiency syndrome, rheumatoid arthritis, and hem

274 on has on the progression of simian acquired immunodeficiency syndrome (SAIDS).

275 The mean reporting completeness for acquired immunodeficiency syndrome, sexually transmitted diseases

276 murine retroviral isolate, develop a severe immunodeficiency syndrome similar to that in humans infe

277 with the dedicator of cytokinesis 8 (DOCK8) immunodeficiency syndrome suffer from recurrent viral an

278 is not integrated into routine HIV/acquired immunodeficiency syndrome surveillance in the United Sta

279 uces a complex disease featuring an acquired immunodeficiency syndrome termed murine AIDS (MAIDS) in

280 ed by slower disease progression to acquired immunodeficiency syndrome than results from HIV-1 infect

281 In acquired immunodeficiency syndrome, the retina is a major site of

282 major problem in patients with the acquired immunodeficiency syndrome, the specific microbial and ho

283 virus (HIV) protease inhibitors in acquired immunodeficiency syndrome therapy.

284 dwide health problems caused by the acquired immunodeficiency syndrome, tuberculosis, and malaria, it

285 of their epitopes in the design of acquired immunodeficiency syndrome vaccines.

286 measles in the setting of a chronic acquired immunodeficiency syndrome virus infection.

287 used to clarify the distribution of acquired immunodeficiency syndrome virus-specific cytotoxic T lym

288 ficiency disease veno-occlusive disease with immunodeficiency syndrome (VODI), which is characterized

289 10% and a positive association with acquired immunodeficiency syndrome were borderline significant (P

290 lymphoma, severe liver disease, and acquired immunodeficiency syndrome were rarely identified among p

291 nodeficiency virus infection or the acquired immunodeficiency syndrome, were referred to the study by

292 f brain tissue from 2 patients with acquired immunodeficiency syndrome who had CMV encephalitis showe

293 immune restoration in patients with acquired immunodeficiency syndrome who have incomplete responses

294 e describe and define a novel CSA and B-cell immunodeficiency syndrome with additional features resem

295 stic syndrome, acute myeloid leukemia and an immunodeficiency syndrome with complex phenotypes includ

296 imelight because it can be linked to primary immunodeficiency syndromes with autoimmunity.

297 a, and human immunodeficiency virus/acquired immunodeficiency syndrome, with significant results.

298 ytes/mm(3)), 90 (18%) progressed to acquired immunodeficiency syndrome within 5 years.

299 e friend or intimate partner to the acquired immunodeficiency syndrome within the prior 6 months.

300 inked agammaglobulinemia and murine X-linked immunodeficiency syndrome (xid).